134 related articles for article (PubMed ID: 38450598)
21. ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides.
Hu X; Deng J; Yu T; Chen S; Ge Y; Zhou Z; Guo Y; Ying H; Zhai Q; Chen Y; Yuan F; Niu Y; Shu W; Chen H; Ma C; Liu Z; Guo F
Gastroenterology; 2019 Mar; 156(4):1098-1111. PubMed ID: 30452920
[TBL] [Abstract][Full Text] [Related]
22. SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.
Xu K; Ding J; Zhou L; Li D; Luo J; Wang W; Shang M; Lin B; Zhou L; Zheng S
Cells; 2022 Dec; 12(1):. PubMed ID: 36611819
[TBL] [Abstract][Full Text] [Related]
23. Circ_0001273 downregulation inhibits the growth, migration and glutamine metabolism of esophageal cancer cells via targeting the miR-622/SLC1A5 signaling axis.
Wu B; Chen Y; Chen Y; Xie X; Liang H; Peng F; Che W
Thorac Cancer; 2022 Jun; 13(12):1795-1805. PubMed ID: 35567340
[TBL] [Abstract][Full Text] [Related]
24. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
25. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
[TBL] [Abstract][Full Text] [Related]
26. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
27. Global Metabolic Profiling Identifies a Pivotal Role of Proline and Hydroxyproline Metabolism in Supporting Hypoxic Response in Hepatocellular Carcinoma.
Tang L; Zeng J; Geng P; Fang C; Wang Y; Sun M; Wang C; Wang J; Yin P; Hu C; Guo L; Yu J; Gao P; Li E; Zhuang Z; Xu G; Liu Y
Clin Cancer Res; 2018 Jan; 24(2):474-485. PubMed ID: 29084919
[No Abstract] [Full Text] [Related]
28. Control of glutamine metabolism by the tumor suppressor Rb.
Reynolds MR; Lane AN; Robertson B; Kemp S; Liu Y; Hill BG; Dean DC; Clem BF
Oncogene; 2014 Jan; 33(5):556-66. PubMed ID: 23353822
[TBL] [Abstract][Full Text] [Related]
29. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
30. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.
Hassanein M; Qian J; Hoeksema MD; Wang J; Jacobovitz M; Ji X; Harris FT; Harris BK; Boyd KL; Chen H; Eisenberg R; Massion PP
Int J Cancer; 2015 Oct; 137(7):1587-97. PubMed ID: 25821004
[TBL] [Abstract][Full Text] [Related]
31. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
32. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
[TBL] [Abstract][Full Text] [Related]
33. Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment.
Yang C; Lee D; Zhang MS; Tse AP; Wei L; Bao MH; Wong BP; Chan CY; Yuen VW; Chen Y; Wong CC
Adv Sci (Weinh); 2022 Dec; 9(34):e2202104. PubMed ID: 36310121
[TBL] [Abstract][Full Text] [Related]
34. CircRNA OXCT1 promotes the malignant progression and glutamine metabolism of non-small cell lung cancer by absorbing miR-516b-5p and upregulating SLC1A5.
Luo H; Peng J; Yuan Y
Cell Cycle; 2023 May; 22(10):1182-1195. PubMed ID: 35482822
[TBL] [Abstract][Full Text] [Related]
35. Circ_0000069 contributes to the growth, metastasis and glutamine metabolism in renal cell carcinoma (RCC) via regulating miR-125a-5p-dependent SLC1A5 expression.
Yang L; Wang L; Wu J; Wang Y
Transpl Immunol; 2023 Apr; 77():101764. PubMed ID: 36462557
[TBL] [Abstract][Full Text] [Related]
36. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
[No Abstract] [Full Text] [Related]
37. Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p/PKM2 Axis Under Hypoxic Stress.
Li Q; Pan X; Zhu D; Deng Z; Jiang R; Wang X
Hepatology; 2019 Oct; 70(4):1298-1316. PubMed ID: 31004447
[TBL] [Abstract][Full Text] [Related]
38. Targeting Pulmonary Fibrosis by SLC1A5-Dependent Glutamine Transport Blockade.
Choudhury M; Schaefbauer KJ; Kottom TJ; Yi ES; Tschumperlin DJ; Limper AH
Am J Respir Cell Mol Biol; 2023 Oct; 69(4):441-455. PubMed ID: 37459644
[TBL] [Abstract][Full Text] [Related]
39. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.
Xia P; Zhang H; Lu H; Xu K; Jiang X; Jiang Y; Gongye X; Chen Z; Liu J; Chen X; Ma W; Zhang Z; Yuan Y
Cancer Commun (Lond); 2023 Mar; 43(3):338-364. PubMed ID: 36602428
[TBL] [Abstract][Full Text] [Related]
40. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
Mu H; Yu G; Li H; Wang M; Cui Y; Zhang T; Song T; Liu C
Cell Oncol (Dordr); 2021 Oct; 44(5):1151-1166. PubMed ID: 34339013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
